Company news

Aspire Biopharma Holdings, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Aspire Biopharma Successfully Launches BUZZ BOMB(TM) Pre-Workout Supplement at FitCon and FitExpo, Two of the Largest Fitness Conventions in the World

August 13, 2025

Aspire Biopharma Holdings, Inc. Unveils E-commerce Platform, Launches with its BUZZ BOMB Pre-Workout Supplement

July 31, 2025

Aspire Biopharma Holdings, Inc. Announces CEO Transition

July 30, 2025

Aspire Biopharma Holdings, Inc. to Launch its BUZZ BOMB Pre-Workout Supplement at FitCon and FitExpo, Two of the Largest Fitness Conventions in the World

July 22, 2025

Aspire Biopharma Holdings, Inc., Announces Positive Consumer Feedback from Company Sampling of BUZZ BOMB(TM), its New Sublingual Pre-Workout Supplement

July 9, 2025

Aspire Biopharma Holdings, Inc., Announces Last Patient Dosed in Phase 1 Clinical Trial of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation

June 24, 2025

Aspire Biopharma Holdings, Inc., Announces Michael C. Howe - With Decades of Experience at Leading and Building Brands in the Healthcare and Consumer Space - To Be Its New Chief Executive Officer

June 10, 2025

Aspire Biopharma Holdings, Inc., Provides Development Update on BUZZ BOMB(TM), its New Sublingual Pre-Workout Supplement, Expected to Launch in Third Quarter of 2025

May 28, 2025

Aspire Biopharma Holdings, Inc., Announces First Patient Dosed in Phase 1 Clinical Trial for its Lead Program, an Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation

May 20, 2025

Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference May 21

May 8, 2025

Aspire Biopharma Holdings, Inc., Announces Institutional Review Board Approval for In-Human Clinical Trial of an Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation

April 29, 2025

Aspire Biopharma Holdings, Inc., to Present at the Emerging Growth Conference on Thursday, April 17

April 14, 2025

Aspire Biopharma Holdings, Inc., Commences Initial Production of its Pre-Workout Performance Supplement

April 11, 2025

Aspire Biopharma Holdings, Inc., Announces Phase 1 Clinical Trial Initiation of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation

April 9, 2025

Aspire Biopharma Holdings, Inc., Contract Manufacturer, Glatt Air Techniques, Inc., has Completed Its First Good Manufacturing Practice (“GMP”) Clinical Batch of Pharmaceutical Grade Oral Mucosal Fast Acting Formulation of Aspirin

March 20, 2025

Aspire Biopharma Holdings, Inc., Provides Update on Recently Filed U.S. Patent Applications for Its Sublingual Drug Delivery Platform

March 13, 2025

Aspire Biopharma Holdings, Inc., to Launch the Next Generation of Pre-Workout Performance Supplement

March 3, 2025

Aspire Biopharma Holdings, Inc., Provides an Update on Lead Product Candidate: High-Dose, Sublingual Aspirin

February 25, 2025

Aspire Biopharma Holdings, Inc. Announces the Execution of Securities Purchase Agreement

February 20, 2025

Aspire Biopharma Holdings, Inc., Announces Public Listing on Nasdaq

February 20, 2025

Aspire Biopharma, Inc., and PowerUp Acquisition Corp. Announce Business Combination Agreement to Create Nasdaq-listed Biopharmaceutical Company Driving Breakthrough Innovations in FDA Approved Drugs, Nutraceuticals and Supplements

September 2, 2024

Aspire Biopharma, Inc. Signs Letter of Intent to Create a Publicly Listed, Drug Delivery Company Through a Business Combination with PowerUp Acquisition Corp.

July 30, 2024

← Newer news releases

Decks

The 5 newest of 6 decks. Every deck is listed under its year.